Literature DB >> 8558999

[Surgical therapy of hepatoblastoma in childhood].

D von Schweinitz1, H Hecker, D Bürger, H Mildenberger.   

Abstract

Hepatoblastoma is a rare but highly malignant liver tumour, predominantly occurring during early childhood. Clinical data of 71 children treated from 1988 to 1993 according to the protocol of the multicentre liver tumour study (HB89) of the German Society for Paediatric Oncology and Haematology were evaluated to assess the effects of surgical therapy in these patients. The protocol prescribed an initial laparotomy for all children with a liver tumour, except for infants with distant metastases and a high serum-alpha-fetoprotein; for small hepatoblastomas confined to one liver lobe primary resection by a lobectomy; and for those extending into both lobes and metastasizing tumours tumour reductive chemotherapy including ifosfamide, cisplatin and adriamycin (IPA), preparatory to resection at second-look surgery. All patients received adjuvant IPA chemotherapy after tumour resection. In 20 of the 71 cases, the hepatoblastomas were completely resected at initial laparotomy (stage I), while in 6 cases microscopic residues were left (stage II). In 38 of 45 children with extended hepatoblastomas (stage III, 38 patients) or distant metastases (stage IV, 7 patients) the tumour was resected during later surgery, and 1 patient received a liver transplant. Thus, the overall resection rate was 92% (65 of 71 hepatoblastomas). After a median follow-up of 3.8 years (range 1.0-5.9 years), 53 (75%) of the patients were tumor-free and 18 (25%) had died. Recurrence-free survival was 100% for stage I, 50% for stage II, 71% for stage III and 29% for stage IV patients (P = 0.0009).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 8558999

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  18 in total

Review 1.  Liver regeneration: molecular mechanisms of growth control.

Authors:  G K Michalopoulos
Journal:  FASEB J       Date:  1990-02-01       Impact factor: 5.191

2.  Growth of mouse hepatoma following liver resection.

Authors:  C J Stolar; K D Anderson
Journal:  J Pediatr Surg       Date:  1980-08       Impact factor: 2.545

3.  [HB89: the liver tumor study of the Society for Paediatric Oncology. An interim report].

Authors:  D Bürger; D von Schweinitz; P Weinel; H Mildenberger
Journal:  Chirurg       Date:  1992-03       Impact factor: 0.955

4.  [Hepatoblastoma: a catamnestic study and proposal of a therapy concept].

Authors:  H Mildenberger; D Bürger; P Weinel
Journal:  Z Kinderchir       Date:  1989-04

5.  The surgical management of children with incompletely resected hepatic cancer is facilitated by intensive chemotherapy.

Authors:  D R King; J Ortega; J Campbell; J Haas; A Ablin; D Lloyd; K Newman; J Quinn; M Krailo; J Feusner
Journal:  J Pediatr Surg       Date:  1991-09       Impact factor: 2.545

6.  Thirty years of experience with pediatric primary malignant liver tumors.

Authors:  M Giacomantonio; S H Ein; K Mancer; C A Stephens
Journal:  J Pediatr Surg       Date:  1984-10       Impact factor: 2.545

7.  Technique and preliminary results of extracorporeal liver surgery (bench procedure) and of surgery on the in situ perfused liver.

Authors:  R Pichlmayr; H Grosse; J Hauss; G Gubernatis; P Lamesch; H J Bretschneider
Journal:  Br J Surg       Date:  1990-01       Impact factor: 6.939

8.  Is laparatomy the first step in treatment of childhood liver tumors?--The experience from the German Cooperative Pediatric Liver Tumor Study HB-89.

Authors:  D von Schweinitz; D Bürger; H Mildenberger
Journal:  Eur J Pediatr Surg       Date:  1994-04       Impact factor: 2.191

9.  Major hepatic tumor resection using profound hypothermia and circulation arrest.

Authors:  S H Ein; B Shandling; W G Williams; G Trusler
Journal:  J Pediatr Surg       Date:  1981-06       Impact factor: 2.545

10.  [Results of the HB-89 Study in treatment of malignant epithelial liver tumors in childhood and concept of a new HB-94 protocol].

Authors:  D von Schweinitz; D Bürger; U Bode; P Weinel; R Erttmann; H Hecker; H Mildenberger
Journal:  Klin Padiatr       Date:  1994 Jul-Aug       Impact factor: 1.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.